Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Phase 1 Completed 13 enrolled Icahn School of Medicine at Mount Sinai

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to characterize the safety and tolerability of avelumab in combination with Laser Interstitial Thermal Therapy (LITT) for blood barrier disruption in patients with recurrent glioblastoma.

Timeline

Start: 2018-06-13
Primary completion: 2021-10-13
Completion: 2021-10-13

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	10 mg/kg	Intravenous

Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Summary

Timeline

Drugs

Indications